{
    "symbol": "SNY",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-28 15:40:40",
    "content": " Looking at sales evolution in the U.S. market, we are pleased by the robust growth of 45% driven by all indications, including our most recent launches in EoE and our AD age expansion down to 6 months of age, which makes Dupixent the first biologic in immunology to be approved in this age group. Wimal, we can\u00e2\u0080\u0099t hear you. Wimal, we can\u00e2\u0080\u0099t hear you. I think when J-B talked about how we\u00e2\u0080\u0099re managing the R&D spend, it was also one of our -- it\u00e2\u0080\u0099s going to cover a bit of work to partner for a low royalty to be able to take the risk with, in this case, Blackstone to get that subcutaneous there whilst not having an opportunity cost on the rest of our pipeline."
}